v3.24.3
LICENSE AGREEMENTS AND ASSET PURCHASE AGREEMENTS (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2024
Apr. 30, 2024
Mar. 31, 2023
Jul. 31, 2022
Mar. 31, 2022
Aug. 31, 2021
Jan. 31, 2021
Oct. 31, 2020
Nov. 30, 2019
Aug. 31, 2019
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Feb. 28, 2019
License Agreements and Asset Purchase Agreements                                
Cost of product sold                     $ 42,778 $ 32,296 $ 102,406 $ 78,084    
Accrued Sales Based Trademark and Royalties $ 40,295                   40,295   40,295   $ 40,419  
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics                                
License Agreements and Asset Purchase Agreements                                
Consideration transferred           $ 3,500                    
Payment for intellectual property upon developmental milestones           19,000                    
Payment for intellectual property upon regulatory milestones           44,000                    
Payment for intellectual property upon sales milestones           $ 110,000                    
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics | Research and development expense                                
License Agreements and Asset Purchase Agreements                                
Payment related to achievement of preclinical milestone 1,000   $ 750                          
Bioprojet                                
License Agreements and Asset Purchase Agreements                                
Licensing agreement milestone fees                   $ 2,000            
License agreement milestone payments paid                 $ 75,000 2,000            
License agreement, additional milestone payment due                   102,000            
Bioprojet | Upon Acceptance by FDA of Pitolisant's                                
License Agreements and Asset Purchase Agreements                                
License agreement, milestone payment due                               $ 50,000
License agreement, upfront non-refundable licensing fees paid       $ 30,000                        
License agreement, maximum additional milestone payment due       $ 155,000                        
Bioprojet | Upon FDA Approval of WAKIX                                
License Agreements and Asset Purchase Agreements                                
License agreement, milestone payment due                   77,000            
Licensing agreement milestone fees                   $ 2,000            
License agreement milestone payments paid             $ 100,000 $ 2,000                
Bioprojet | Sales-based, trademark and tiered royalties                                
License Agreements and Asset Purchase Agreements                                
Cost of product sold                     40,295 $ 29,665 95,232 $ 71,267    
Accrued Sales Based Trademark and Royalties $ 40,295                   $ 40,295   $ 40,295   $ 40,419  
Bioprojet | Orexin-2 receptor agonist (OX2R)                                
License Agreements and Asset Purchase Agreements                                
Payment of upfront license fee   $ 25,500                            
Amount of fee payable upon achieving development and regulatory milestones   127,500                            
Amount of fees payable upon achieving sale-based milestones   $ 240,000                            
Bioprojet | United States                                
License Agreements and Asset Purchase Agreements                                
Amount of Aggregate Net Sales Attaining         $ 500,000                      
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX                                
License Agreements and Asset Purchase Agreements                                
Final payment paid         $ 40,000